SQUAWK/NEWS
Menu
Live News EQUITY M impact

Mizuho initiates CNTY at Outperform

Mizuho starts coverage of Century Therapeutics with Outperform rating, citing potential growth prospects

CNTY

Mizuho starts coverage of Century Therapeutics with Outperform rating, citing potential growth prospects